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Histamine-release r sponses in clinical conditions 
show a wide range of severity, from a single spot of 
erythema or a wheal up to a life-threatening reaction or 
the death of the patient. 
To demonstrate he efficiency of Hi- and HE-blockade 
in preventing histamine-induced anaphylactic and 
anaphylactoid reactions, a series of controlled trials was 
carried out in patients, volunteers and dogs presenting 
histamine-release r sponses of all three grades of 
severity (table I). Both the histamine-releasing drugs 
and the histamine H1- and HE-receptor antagonists had to 
be chosen for these trials according to a series of 
well-conceived and strict criteria. 
For the histamine H1- and HE-receptor antagonists, 
the criteria for selection included potency, selectivity, 
duration of action, clinical experience with the drug and 
the availability both for tlae oral and the intravenous 
routes. For the HE-receptor antagonist, selection was not 
difficult since, at the time of the first trials, cimetidine 
was the only available drug on the market. However, the 
choice of the Hi-receptor antagonist was very difficult. 
Dimethindene (Forhistal ® in the USA, Fenistil ® in 
Europe) was chosen since it is very potent [12, 14], 
highly selective [11, 14], its duration of action was long 
enough for 2-3 h of operation, but not too long-lasting 
to interfere with postoperative recovery, and the drug 
did not release histamine in man [6]. 
Five controlled clinical and experimental trials were 
conceived and carried out in the last six years, a 
synopsis of which has been compiled in table II. 
Materials and methods of all these trials have been 
described in previous communications [4, 9, 10, 13]. In 
Table I. - -  Classification of histamine-release responses by severity as a special form of anaphylactoid reactions to drugs or physical injury 
Severity grade Clinical symptoms Operational criteria Plasma 
and groups of symptoms histamine 
I. Cutaneous - -  Erythema, urticaria and/or dermal - -  Not considered as threatening ~<l ng - m1-1 
pruntus only - -  No intensified observation, no treat- 
ment 
II. Systemic - -  Generalized skin reactions plus dis- - -  Considered as threatening by patient > 1 ng • ml 
comfort and doctor 
- -  Tachycardia, arrhythmias, medium - -  Intensified observation and/or treat- 
hypotension ment 
- -  Respiratory distress 
III. Life-threatening - -  Severe hypotension (pulse and RR not - -  Considered as life-threatening by >12 ng• m1-1 
measurable) doctor 
- -  Ventricular fibrillations, cardiac - -  Emergency treatment 
arrest 
- -  Bronchospasm, respiratory arrest 
From LORENZ et al. [7]. 
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Table I1. - -  Synopsis of five randomized controlled trials on prevention of anaphylactoid reactions to several h~stamine r leasers with histamine 
H~- + H2-receptor antagonists 
N ° Severity grade Histamine releaser H1- + H2-antagonists 
(ml and mg• kg -l  i.v. (mg • kg -1 i.v.) 
respectively) 
Frame of the trial 
(Individuals, location 
and time) 
1 Cutaneous Polygeline-35 
7 ml • kg-1, 
10-15 min infusion 
2 Systemic Classical polygeline 
7 ml • kg - l ,  
3 min, after bleeding 
3 Systemic Propanidid (Epontol ®) 
in Micellophor (2x) 
7 mg'kg  -1, 60 s 
4 Life-threatening Classical polygeline 
20 ml • kg -1, 
3 min, after bleeding 
5 Life-threatening 48/80 in Ringer 
20 ml • kg -1, 
3 min, after bleeding 
H~ Fenistil 
Piriton 
H 2 Tagamet 
HI Fenistil 






H1 : Fenistil O. 1 
He : Tagamet 5.0 
H1 Fenistil 









single and double-blind, 
450 patients, Heidelberg 1979/80 
Randomized controlled, 
single and double-blind, 
50 volunteers, Munich 1977 
Randomized, cross-over, 
single and double-blind, 
32 volunteers, Munich 1979 
Randomized, controlled, 
single and double-blind, 
40 dogs, Marburg 1977 
Randomized controlled, 
single and double-blind, 
84 dogs, Marburg 1982 
Fenistil ® = dimethindene maleate; Piriton ® = chlorpheniramine; Tagamet ®= cimetidine. For details and further conditions, ee [t, 7, 10]. 
this paper, we only report the main results of the four 
trials, excluding that with propanidid. 
1. Cutaneous anaphylactoid reactions 
to polygeline 35 in patients 
In contrast to the now outdated formulation of 
polygeline (~ classical ~ Haemaccel®), ~ purified ~ 
polygeline (Haemaccel 35) did not elicit any systemic 
anaphylactoid reactions in patients (table III). There still 
were, however, cutaneous anaphylactoid reactions. They 
only consisted of wheals of 2-3 mm diameter and 
caused, if nothing else was detectable, itching and 
burning which was usually neglected by the patients 
expecting surgery. The incidence of this banal hista- 
mine-release response to polygeline was less than in 
studies with ~ classical ~ Haemaccel [7], but still 18% ! 
However, by premedicating with H1- and H2-receptor 
antagonists, it was drastically reduced, not only in the 
overall number of reactions (table III), but also in the 
~ severity >~ of those remaining. Dimethindene was 
superior to chlorpheniramine. Since the premedication 
was administered slowly (2 min for each drug), there 
were no side-effects of the H 1- and Ha-blockade in such 
Table III. - -  Cutaneous anaphylactoid reactions in patients 
receiving three kinds of premedication and subsequent infusion 
of ,, purified ,, polygeline (Haemacce135) 




Saline 0 27 123 150 
Fenistil plus 0 4 146 150 
Tagamet (Hi+H2) 
Piriton plus 0 9 141 150 
Tagamet (Hi+H2) 
Total 0 40 410 450 
Total (H1 + H2) versus saline : X 2 = 24.11 (p <0.005). 
Fenistil ® = dimethindene maleate; Piriton ® = chlorpheniramine; 
Tagamet ®= cimetidine. For further conditions, see SCHOmNG et 
al. [13]. 
Table IV. - -  Anaphyl.actoid reactions and other clinical symptoms in 
volunteers following H1 +H2-blockade and isovolaemic haemo- 
dilution with classical polygeline 
Reactions and Incidence 
symptoms Hi + H2 Saline 
blockade premedication 
Cutaneous reaction 0/25 3/25 
Systemic reaction 0/25 6/25 * 
Severity grade I + II 0/25 9/25 ** 
Flush 1/25 6/25 
Feeling of heat 12/25 17/25 
Metallic taste 2/25 5/25 
Other qualities of taste 15/25 14/25 
X2-test : * p <0.05; ** p <0.01. For further conditions, ee [4, 9, 
131. 
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a relatively large sample of 300 patients. Basal plasma 
histamine concentrations were in the normal range and 
did not rise to a pathological level (>1 ng • m1-1) in 
any of the subjects [13]. In addition, no difference in 
plasma histamine levels could be detected between 
subjects with ~< no reaction ~ and those with a , cuta- 
neous reaction ~. 
The most remarkable result of this trial in patients was 
the suppression of urticaria by H1- and HE-receptor 
antagonists. 
2. Systemic anaphylactoid reactions 
to outdated polygeline 
(,, classical ,, Haemaccel) in human volunteers 
This clinical trial was the first study in human subjects 
with HI -  and HE-receptor antagonists at a time when 
purified polygeline (Haemaccel 35) has not yet been 
developed. In those test subjects who received saline as 
-premedication >~ followed by a rapid infusion of 
classical polygeline, three cutaneous and six systemic 
reactions were observed. The overall incidence of 
adverse reactions was 9/25, i .e.  36 %!  In those 
volunteers who received the H1- and HE-blockade, no 
reactions occurred, not even a single spot of erythema or 
a single wheal and flare-response (table IV). Two of the 
six systemic reactions were quite severe: mild bron- 
chospasm, generalized urticaria with great discomfort 
(blepharoedema, cough, sneezing, stuffy nose) and 
subjective fear for life in combination with tachycardia 
and mild hypertension. 
The maximum plasma histamine levels in these two 
subjects were only about 2 ng • m1-1 (table V). 
However, they were pathological as well as all of the 
values in the four other subjects suffering from a 
systemic response. In the test group receiving the H I - 
and HE-blockade, seven volunteers released histamine to 
greater levels than in the control group, including two 
subjects with plasma histamine concentrations of 
5 ng • m1-1, at the top of the Bateman curve. Since in 
all previous studies (see especially [5, 7]), increasing 
plasma histamine levels to this order of  magnitude 
always caused anaphylactoid reactions of a considerable 
severity, the complete prevention of any clinical signs 
and cardiovascular reactions in these subjects was very 
remarkable. The result of this trial justified the defini- 
tion of histamine release as predominant in the adverse 
reaction to polygeline [2]. 
3. Life-threatening anaphylactoid reactions 
to outdated polygeline (,, classical- Haemaccel) 
For ethical reasons, this trial could be conducted only 
in experimental nimals. All dogs except one reacted to 
~ classical ~ Haemaccel by systemic histamine-release 
responses (table VI). More than half of them were 
life-threatening with falls in blood pressure of more than 
100 mmHg. 
H1- and HE-receptor antagonist premedication did not 
significantly change the extent of histamine release 
elicited by polygeline, but the hypotensive response was 
drastically reduced (table VI). On the average, the fall in 
blood pressure was completely prevented. In the least 
successful pretreatment, the blood pressure fall by 
50 mmHg - -a  reaction which was well tolerated without 
any treatment and which disappeared after 20 min. 
This was the first controlled trial which showed that 
life-threatening histamine-release is prevented by H1- 
and Hz-blockade. Apparently, this type of prophylaxis 
could be successfully used in patients at risk of 
presenting a severe anaphylactoid and anaphylactic 
reaction. 
Table V. - -  Tachycardia nd hypertension following rapid infusion of classical polygeline in volunteers with systemic anaphylactoid reactions, 
but pretreated with placebo (saline) or H1- + H2-blockers 
Saline H 1 + HE-receptor antagonists 
N ° Plasma histamine Hypertension Tachycardia N ° Plasma histamine Hypertension T'achycardia 
level (ng • m1-1) (mmHg) (c • min -1) level (ng • m1-1) (mmHg) (c • min -a) 
before after before after 
3 0.1 1.25 10/5 12 2 0.3 1.8 0 0 
16 0.2 1.8 * 20/10 26 17 0.3 5.1 0 0 
41 0.3 1.2 * 0 23 21 0.25 1.5 0 0 
44 0.6 1.0 0 22 22 0.2 4.95 0 0 
47 0.25 1.05 0 0 25 0.1 3.05 0 0 
48 0.1 1.0 0 16 28 0.5 1.05 5/5 0 
34 0.75 1.3 0 0 
Total 0.25 1.15 2/6 5/6 Total 0.3 1.8 1/7 0/7 
(0.1-0.6) (1.0-1.8) (0.1-0.75) (1.05-5.1) 
Numbers according to the course of the controlled trial. ~ (range) or incidences. Hypertension assystolic/diastolic pressure. * subjects uffering 
from a considerable, but in the doctor's opinion ot life-threatening reaction. Significance inFisher's exact est : p <0.05 for tachycardia. Values 
given as maximum responses inplasma histamine, hypertension a d tachycardia (1min after the end of the polygeline infusion). For further 
conditions, see SCHONING et al. [13]. 
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Table VI. - -  Prevention of severe, life-threatening anaphylactoid 
reactions in dogs following rapid infusion of classical polygeline 
by premedication with H1- + H2-receptor antagonists 
Rank Increase in histamine Hypotension 
(ng/ml) (mmHg) 
Saline HI + H2 Saline HI + H2 
1 5 .3  0 0 0 
2 10.1 1.2 30 0 
3 21.3 2.9 35 0 
4 37.5 8.4 60 0 
5 42.5 19.6 110 0 
6 55.2 22.7 120 0 
7 69.4 48.7 140 0 
8 72.0 52.2 150 30 
9 107.5 62.2 170 30 
10 - -  91 .3  - -  40 
11 - -  113.7 - -  50 
Median 42.5 22.7 * 110 0 ** 
(Range) (5.3-107.5) (0-113.7) (0-170) (0-50) 
Investigators measuring blood histamine levels were not aware of 
the blood pressure responses. Investigators injecting the premedi- 
cation did not know the composition of the fluid used in the 
syringes. Increase in blood histamine levels and hypotension 
(decrease in systolic blood pressure) are given for the time of 
maximum response (about 1-5 min after the end of the infusion). 
Statistical analysis using the Mann-Whitney test : saline versus HI 
+ H2; * Increase in histamine (not significant); ** Hypotension 
(p <0.01). Note that the median is 0, which is different from the 
mean, but the frequency distribution of the values does not 
resemble a normal distribution. 
4. Life-threatening anaphylactoid reactions 
to a reduced dose of compound 48/80 dissolved 
in Ringer's solution 
To imitate life-threatening anaphylactoid reactions in 
surgical patients in the perioperative period with an 
experimental design in animals, a dog model was 
developed. In adult mongrel dogs of both sexes, 
barbiturate anaesthesia was maintained for two and a 
half hours; after an interval of 20 min for achieving 
homeostasis, 1/3 of the blood volume was taken by 
arterial bleeding and, after one minute, restored within 
3 min by the same volume of Ringer solution. Com- 
pound 48/80 was dissolved in this solution at a 
concentration which in prior experiments had been 
shown to increase plasma histamine levels to the same 
extent as in life-threatening anaphylactoid reactions in 
man [10]. 
Dimethindene was given i.v. in the two doses of 
0.1 and 0.5 mg • kg-a together with cimetidine 
(5 mg • kg-a).  The time intervals between prophylaxis 
and the histamine-releasing event were 5 min (induction 
of anaesthesia), 60 min (minor surgery) and 120 min 
(major surgery). The time of application was 2 min for 
cimetidine (first) and 2 min for dimethindene (se- 
cond). 
Using saline as << premedication ~, a mid fall in blood 
pressure of 75 mmHg was obtained in the 12 dogs of the 
control group (fig. 1). This severe response was consi- 
dered as life-threatening when compared to the clinical 
situation. Quite remarkably, however, the dose of 
compound 48/80 used in these experiments caused very 
variable histamine releases as measured by the plasma 
histamine levels (fig. 2). This was exactly what happens 
in clinical conditions when a drug is safe in most 
individuals, whilst causing severe side-effects in a 
minority of other subjects. For this reason, the reactions 
to 48/80 in the control group were considered as proof 
of the clinical relevance of the animal model. 
The hypotensive reactions in all groups of the clinical 
trial were compiled in table VII. The premedication with 
Ha- and Ha-blockers did not prevent he fall in arterial 
blood pressure, but the severity of the reactions was so 
much reduced that Ha- and H2-blockade was considered 
as sufficiently successful. On average, the hypotensive 
response to 48/80 was inhibited in the 5 min-interval 
group by 70 %, this being the same for the low and high 
doses of Hi-receptor antagonist. However, in the 
60 min-interval group, the effect of Ha- and Ha- 
Bleeding (25 ml/kg) - Ringer (25 ml/kg) - 48/80 (50 tag/kg) 








o I 1 ! 
0 5 10 15 
Dogs with histamine - release response [n] 
Fig. 1. - -  Hypotensive reactions in dogs during life-threatening 
anaphylactoid reactions following bleeding and rapid infusion of 
Ringer solution containing 50 ~xg • kg-1 48/80. Single values from 
12 dogs in the control group (saline as premedication, 5 min 
interval between placebo medication and bleeding of 1/3 of the 
blood volume, followed 1 min later by infusion of the same 
volume of Ringer solution within 3 min. For further conditions, 
see LORENZ et al. [10]. 
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Fig. 2. - -  Plasma histamine levels in the first three groups of dogs in the controlled trial on life-threatening anaphylactoid reactions 
following bleeding and rapid infusion of Ringer solution containing 50 ~tg " kg -~ 48/80. Single values from 12 dogs in the control group and 
in two treatment groups. The differences in the plasma histamine levels in the three groups were statistically not significant using an analysis 
of variance for the whole study design. For further conditions, see figure 1 and LORENZ et al. [10]. 
Table VII. - -  Hypotension in dogs following H1 + H2-blockade and 
isovolaemic haemodilution with 25 ml-kg -1 Ringer solution 
containing 48/80 (50 ~g • kg -1) 
Table VIII. m Plasma histamine levels in dogs following 
H~ + H2-blockade and isovolaemic haemodilution with Ringer 
solution containing 48/80 
Time after Hypotension (mmHg) Time after Plasma histamine level (ng" ml - l )  
premedication premedication 
(rain) Saline Hi + H2 HI + H2 (min) Saline H~ + H2 H1 + H2 
5 75 23 * 28 * 5 71 31 48 
(0-115) (0-65) (0-70) (2-461) (1-497) (3-148) 
60 - -  33 * 15 * 60 - -  18 * 14 * 
(0-65) (0-90) (0.3-155) (3-94) 
120 - -  20 * 8 ** 120 - -  20 * 9 ** 
(0-80) (0-60) (0.2-80) (1-37) 
Median values and range in 12 animals of each group. H I :  
dimethindene (0.1 or 0 .5mg-kg  - I  i.v.), H2:  cimetidine 
(5 mg • kg -1 i.v.), Statistical testing by analysis of variance :
• p <0.05 and ** p <0.01. For further conditions, see LORENZ et 
al. [10]. 
Mean values and range in 12 animals of each group. H i :  
dimethindene (0.1 or 0 .5mg .kg  -1 1.v.), H2:  cimetidine 
(5 mg • kg -1 i.v.). Statistical testing by analysis of variance : 
• p <0.05; ** p <0.01. For further conditions, see LORENZ et al. 
[10]. 
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blockade was not diminished - -as  expected from the 
data on the phannacokinetics of the two drugs-- but 
enhanced in the group with the higher dose of HI- 
antagonist. This unexpected reaction was more pro- 
nounced in the 120 min-interval group and led to an 
inhibition of the hypotensive response to 48/80 by 
90%!  
This tremendous attenuation of the life-threatening 
histamine-release response was explained by the data on 
plasma histamine levels which were obtained in the 
same controlled trial (table VIII). The histamine release 
due to 48/80 was reduced in all groups of the 60 min- 
and 120 min-intervals by Ha- and He-blockade. Thus, 
the H l- and He-blockade showed a dual mechanism of 
action : blocking histamine at the receptors, and increas- 
ing with time the blocking of histamine release from 
mast cells. 
In the 5 min-interval group, the hypotension elicited 
by 48/80 was diminished to such an extent hat the blood 
pressure did not fall below 80 mmHg in any of the dogs. 
In one of the 60 min-interval and 120 min-interval 
groups, one of the dogs suffered from a fall in blood 
pressure below this critical value. Thus, reasonable 
protection against life-threatening reactions to 48/80 was 
achieved in 70 of 72 dogs, corresponding to 97 % of the 
animals. 
Thus, premedication with dimethindene and cimeti- 
dine was shown to be effective enough to protect the 
individual against histamine-release r sponses of any 
degree of severity. 
5. Analysis of the clinical relevance 
of the anti-H1 + anti-H2 trials 
(Discussion) 
The question as to whether our patients need H 1- and 
H2-blockade in the perioperative period as a new and 
additional premedication is a matter for clinical deci- 
sion-making. Twenty-three trials in patients and volun- 
teers showed an overall incidence of 30 % of anaphylac- 
toid reactions of all grades of severity (table I) and about 
1-5 % systemic and 0.1-0.5 % life-threatening reactions 
[101. 
Anaphylactoid reactions and histamine-release r s- 
ponses are never considered as beneficial but are 
judged as unwanted effects, however to a different 
degree :
Skin rashes, flush and wheal or flare responses, even 
clinically classified as banal, are usually unpleasant, 
inconvenient and, because of itching, sometimes really 
tormenting. Thus, also, grade I severity reactions cannot 
be completely neglected, especially in the immediate 
postoperative period during which patients very often 
suffer considerably from itching. 
Systemic anaphylactoid reactions are unwanted effects 
of drugs and treatments in the perioperative period, but 
the extent to which they are unwanted effects varies 
considerably from anaesthetist to anaesthetist, and the 
surgeon usually does not take care of them in any case. 
Discarding all histamine-releasing drugs and surgical 
manoeuvres at present is impossible, considering the 
tremendous number of different drugs and manipulations 
in surgery which elicit histamine release in the periop- 
erative period. However, in the patient whit car- 
diovascular and respiratory risk any systemic reaction 
can be life-threatening, as shown in a case with Palacos 
implantation [10]. 
Prophylaxis with histamine H~- and H2-receptor 
antagonists was shown to be effective and safe and can 
therefore fill the gap between the present status of 
perioperative risks due to histamine release and the final 
aim of ~ histamine-free anaesthesia and surgery ~. 
6. Conclusion and recommendations 
We think it is time to use the premedication to avoid 
unnecessary cases of death in surgical patients who have 
a higher risk of histamine-release responses than normal 
subjects or who suffer more than normal individuals 
from the effects of released histamine because they are 
old or poor-risk patients. For this reason, we do not 
longer hesitate in recommending H~- and Ha-blockade 
for surgical patients who: 
- -  have a case history of hypersensitivity reactions to 
intravenous agents (anaesthetics, analgesics, contrast 
media, plasma substitutes, etc.); 
- -have  a history of atopy (hay fever, asthma, 
allergic food reactions), cardiac and/or pulmonary dis- 
ease; 
- -  will undergo a second drug exposure within a few 
days, even if there was no reaction the first time they 
received the drug; 
- -  undergo surgery with a high risk of histamine 
release (transplantation, implantation of bone cement, 
extracorporeal circulation); 
- -  are older than 70 years; 
- -  are poor-risk patients with preoperative cardiac, 
respiratory or liver insufficiency and shock. 
In a general hospital, these patients will comprise 
about 30 % of all patients admitted for surgery [9]. 
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